Limits...
Characterization of the Expression of the RNA Binding Protein eIF4G1 and Its Clinicopathological Correlation with Serous Ovarian Cancer

View Article: PubMed Central - PubMed

ABSTRACT

Background: Ovarian cancer is the most lethal type of malignant tumor in gynecological cancers and is associated with a high percentage of late diagnosis and chemotherapy resistance. Thus, it is urgent to identify a tumor marker or a molecular target that allows early detection and effective treatment. RNA-binding proteins (RBPs) are crucial in various cellular processes at the post-transcriptional level. The eukaryotic translation initiation factor 4 gamma, 1(eIF4G1), an RNA-binding protein, facilitates the recruitment of mRNA to the ribosome, which is a rate-limiting step during the initiation phase of protein synthesis. However, little is known regarding the characteristics of eIF4G1 expression and its clinical significance in ovarian cancer. Therefore, we propose to investigate the expression and clinicopathological significance of eIF4G1 in ovarian cancer patients.

Methods: We performed Real-time PCR in 40 fresh serous ovarian cancer tissues and 27 normal ovarian surface epithelial cell specimens to assess eIF4G1mRNA expression. Immunohistochemistry (IHC) was used to examine the expression of eIF4G1 at the protein level in 134 patients with serous ovarian cancer and 18 normal ovarian tissues. Statistical analysis was conducted to determine the correlation of the eIF4G1 protein levels with the clinicopathological characteristics and prognosis in ovarian cancer.

Results: The expression of eIF4G1 was upregulated in serous ovarian cancer tissues at both the mRNA (P = 0.0375) and the protein (P = 0.0007) levels. The eIF4G1 expression was significantly correlated with the clinical tumor stage (P = 0.0004) and omentum metastasis (P = 0.024). Moreover, patients with low eIF4G1 protein expression had a longer overall survival time (P = 0.026).

Conclusions: These data revealed that eIF4G1 is markedly expressed in serous ovarian cancer and that upregulation of the eIF4G1 protein expression is significantly associated with an advanced tumor stage. Besides, the patients with lower expression of eIF4G1 tend to have a longer overall survival time. Thus, eIF4G1 may contribute to the occurrence and metastasis of ovarian cancer and can serve as a potential therapeutic target for the treatment of ovarian cancer.

No MeSH data available.


Post-surgical overall survival correlates with eIF4G1 protein expression in ovarian cancer.(A) Overall survival rates for cases with high eIF4G1 expression versus cases with low eIF4G1 expression levels in ovarian cancer patients. (B) Post-surgical progression free survival rates for cases with high eIF4G1 expression versus cases with low eIF4G1 expression levels in ovarian cancer patients. There were 40 patients with low eIF4G1 expression and 93 patients with high eIF4G1 expression. However, due to missing survival data, only 72 and 79 patients with high eIF4G1 as well as 28 and 31 patients with low eIF4G1 expression were included for progression-free survival analysis and overall survival analysis, respectively.
© Copyright Policy
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC5036801&req=5

pone.0163447.g006: Post-surgical overall survival correlates with eIF4G1 protein expression in ovarian cancer.(A) Overall survival rates for cases with high eIF4G1 expression versus cases with low eIF4G1 expression levels in ovarian cancer patients. (B) Post-surgical progression free survival rates for cases with high eIF4G1 expression versus cases with low eIF4G1 expression levels in ovarian cancer patients. There were 40 patients with low eIF4G1 expression and 93 patients with high eIF4G1 expression. However, due to missing survival data, only 72 and 79 patients with high eIF4G1 as well as 28 and 31 patients with low eIF4G1 expression were included for progression-free survival analysis and overall survival analysis, respectively.

Mentions: In order to determine whether there is any relationship between the level of eIF4G1 expression and the prognosis in ovarian cancer patients, we performed Kaplan–Meier analysis and the log-rank test. Patients who have lower eIF4G1 levels tend to experience a longer overall survival time (P = 0.026). However, the log-rank test showed that no difference in progression-free survival (P = 0.182) (Fig 6).


Characterization of the Expression of the RNA Binding Protein eIF4G1 and Its Clinicopathological Correlation with Serous Ovarian Cancer
Post-surgical overall survival correlates with eIF4G1 protein expression in ovarian cancer.(A) Overall survival rates for cases with high eIF4G1 expression versus cases with low eIF4G1 expression levels in ovarian cancer patients. (B) Post-surgical progression free survival rates for cases with high eIF4G1 expression versus cases with low eIF4G1 expression levels in ovarian cancer patients. There were 40 patients with low eIF4G1 expression and 93 patients with high eIF4G1 expression. However, due to missing survival data, only 72 and 79 patients with high eIF4G1 as well as 28 and 31 patients with low eIF4G1 expression were included for progression-free survival analysis and overall survival analysis, respectively.
© Copyright Policy
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC5036801&req=5

pone.0163447.g006: Post-surgical overall survival correlates with eIF4G1 protein expression in ovarian cancer.(A) Overall survival rates for cases with high eIF4G1 expression versus cases with low eIF4G1 expression levels in ovarian cancer patients. (B) Post-surgical progression free survival rates for cases with high eIF4G1 expression versus cases with low eIF4G1 expression levels in ovarian cancer patients. There were 40 patients with low eIF4G1 expression and 93 patients with high eIF4G1 expression. However, due to missing survival data, only 72 and 79 patients with high eIF4G1 as well as 28 and 31 patients with low eIF4G1 expression were included for progression-free survival analysis and overall survival analysis, respectively.
Mentions: In order to determine whether there is any relationship between the level of eIF4G1 expression and the prognosis in ovarian cancer patients, we performed Kaplan–Meier analysis and the log-rank test. Patients who have lower eIF4G1 levels tend to experience a longer overall survival time (P = 0.026). However, the log-rank test showed that no difference in progression-free survival (P = 0.182) (Fig 6).

View Article: PubMed Central - PubMed

ABSTRACT

Background: Ovarian cancer is the most lethal type of malignant tumor in gynecological cancers and is associated with a high percentage of late diagnosis and chemotherapy resistance. Thus, it is urgent to identify a tumor marker or a molecular target that allows early detection and effective treatment. RNA-binding proteins (RBPs) are crucial in various cellular processes at the post-transcriptional level. The eukaryotic translation initiation factor 4 gamma, 1(eIF4G1), an RNA-binding protein, facilitates the recruitment of mRNA to the ribosome, which is a rate-limiting step during the initiation phase of protein synthesis. However, little is known regarding the characteristics of eIF4G1 expression and its clinical significance in ovarian cancer. Therefore, we propose to investigate the expression and clinicopathological significance of eIF4G1 in ovarian cancer patients.

Methods: We performed Real-time PCR in 40 fresh serous ovarian cancer tissues and 27 normal ovarian surface epithelial cell specimens to assess eIF4G1mRNA expression. Immunohistochemistry (IHC) was used to examine the expression of eIF4G1 at the protein level in 134 patients with serous ovarian cancer and 18 normal ovarian tissues. Statistical analysis was conducted to determine the correlation of the eIF4G1 protein levels with the clinicopathological characteristics and prognosis in ovarian cancer.

Results: The expression of eIF4G1 was upregulated in serous ovarian cancer tissues at both the mRNA (P = 0.0375) and the protein (P = 0.0007) levels. The eIF4G1 expression was significantly correlated with the clinical tumor stage (P = 0.0004) and omentum metastasis (P = 0.024). Moreover, patients with low eIF4G1 protein expression had a longer overall survival time (P = 0.026).

Conclusions: These data revealed that eIF4G1 is markedly expressed in serous ovarian cancer and that upregulation of the eIF4G1 protein expression is significantly associated with an advanced tumor stage. Besides, the patients with lower expression of eIF4G1 tend to have a longer overall survival time. Thus, eIF4G1 may contribute to the occurrence and metastasis of ovarian cancer and can serve as a potential therapeutic target for the treatment of ovarian cancer.

No MeSH data available.